Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 12/20 | 0.53 |
| ▸ | JAK1 | P23458 | 10/20 | 0.53 |
| ▸ | JAK2 | O60674 | 7/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.44 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.42 |
| ▸ | FEN1 | P39748 | 2/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | PRKCA | P17252 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16249709 | 0.77 | JAK1 (0.49) | JAK3JAK1JAK2 | |
| SCHEMBL2376996 | 0.76 | JAK3 (0.70) | JAK3JAK1JAK2 | |
| SCHEMBL27855946 | 0.75 | JAK3 (0.63) | JAK3JAK1JAK2MAPK1 | |
| SCHEMBL415512 | 0.74 | JAK3 (0.55) | JAK3JAK1JAK2 | |
| SCHEMBL13746757 | 0.73 | JAK3 (0.40) | JAK3JAK1JAK2 | |
| SCHEMBL12799404 | 0.72 | MAPK1 (0.47) | JAK3JAK1JAK2MAPK1 | |
| SCHEMBL2105029 | 0.71 | JAK3 (0.62) | JAK3JAK1JAK2AURKAPRKCA | |
| SCHEMBL30208780 | 0.71 | ALOX5AP (0.52) | JAK3JAK1JAK2MAPK1ALOX5AP | |
| SCHEMBL30208814 | 0.71 | ALOX5AP (0.55) | JAK3JAK1JAK2MAPK1ALOX5AP | |
| SCHEMBL2319051 | 0.71 | JAK3 (0.51) | JAK3JAK1JAK2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902197-B2 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2011-03-08 | — | — | US | disclosed |
| US-7902197-B2 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2011-03-08 | — | — | US | disclosed |
| US-20090215788-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2009-08-27 | — | — | US | disclosed |
| US-20090215788-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215788-A1 | Pyrrolopyrazine kinase inhibitors | SYK, ZAP70, JAK2 | JAK3 7/4885JAK1 4/4885JAK2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.